Thrombosis Risk Examined in Myeloproliferative Neoplasms

Higher rates of thrombosis compared to matched controls; risk highest at and soon after diagnosis
Higher rates of thrombosis compared to matched controls; risk highest at and soon after diagnosis

HealthDay News — Patients with myeloproliferative neoplasms (MPNs) have increased risk of arterial thrombosis and venous thrombosis across all age groups and MPN subtypes, according to a study published online January 16 in the Annals of Internal Medicine.

Malin Hultcrantz, MD, PhD, from Karolinska University Hospital and Karolinska Institutet in Stockholm, and colleagues examined the risk for arterial and venous thrombosis seen in patients with MPNs versus control participants in a population-based setting. Data were included for 9,429 patients with MPNs and 35,820 matched control participants in Sweden from 1987 to 2009, with follow-up to 2010.  

Similar Articles

The researchers found that, compared with control participants, for patients with MPNs, the hazard ratios for arterial thrombosis were 3.0, 2.0, and 1.5 at 3 months, 1 year, and 5 years, respectively. For venous thrombosis, the corresponding hazard ratios were 9.7, 4.7, and 3.2. Across all age groups, the rate was significantly increased and was similar for MPN subtypes. In patients with MPNs, the 5-year cumulative incidence of thrombosis showed an initial rapid increase followed by a smaller increase during follow-up. During more recent calendar periods, the hazard ratio for venous thrombosis decreased.

"Patients with MPNs across all age groups have a significantly increased rate of arterial and venous thrombosis compared with matched control participants, with the highest rates at and shortly after diagnosis," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)